CW March 2004
Volume 13Issue Number 3 March 2004 ISSN 10593802 Sorting the Options in First-Line Advanced Colorectal CancerWith the advent of newer therapies, options have broadened and outcomes improved, according to a 9th Annual National Comprehensive Cancer Network Meeting presentation. Three key agents underlie major options: oxaliplatin, irinotecan, and bevacizumab.
Go to Previous Page Go to Next Page Source & Additional Reading R. Diasio, 9th Annual National Comprehensive Cancer Network Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW March 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
